指南与共识美容整形乳房整形与再造

乳房隆胸术中阿片类药物处方实践评估:处方指南的未来方向

Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines.
指南 / 共识 · Ann Plast Surg · 2021-01-01

该研究通过电子问卷调查美国美容整形外科学会成员,评估乳房隆胸术后的阿片类药物处方模式。

要点

  • 乳房隆胸术后阿片类药物处方存在显著差异,平均165.3 MMEs。
  • 91.2%的受访者常规开具阿片类药物,以羟考酮/对乙酰氨基酚为主。
  • 61.3%受访者支持制定整形外科学会阿片类药物处方指南。

核心结论

  • 乳房隆胸术后阿片类药物处方模式存在显著差异,学会指南可能在未来发挥规范作用。

研究设计与样本

  • 研究为横断面电子问卷调查,对象为美国美容整形外科学会成员,共发放1709份问卷。

主要发现

  • 最常处方的药物为羟考酮/对乙酰氨基酚(Percocet,47.0%)和氢可酮/对乙酰氨基酚(Vicodin,38.3%)。
  • 平均处方165.3±81.7 MMEs(范围25.0-600.0 MMEs;片数5-60片)。
  • 52.4%的处方者认为缺乏电话处方和易于预先开具阿片类药物助长了过度处方。
  • 61.3%的受访者表示支持或可能支持制定整形外科学会阿片类药物处方指南。

关键数值与推荐

  • 支持指南的受访者中,74.2%支持阿片类药物节约型疼痛管理策略。
  • 54.7%支持指南明确药物类型,69.5%支持明确使用时长,61.7%支持明确片数。

临床怎么用

  • 临床可参考平均165.3 MMEs的处方量,但需注意个体差异及指南缺失现状。
  • 优先考虑阿片类药物节约型多模式镇痛策略,减少不必要的阿片类药物暴露。

局限性

  • 问卷回应率仅13.4%,可能存在无应答偏倚。
  • 研究仅反映美国美容整形外科学会成员的自报处方模式,外推性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted. METHODS: Members of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate. RESULTS: Two hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0-600.0 MMEs; number tablets, 5-60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures. CONCLUSIONS: Considerable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Crystal DT, Cuccolo NG, Plewinski MJ, et al. Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines. Ann Plast Surg. 2021. PMID: 32568754. doi:10.1097/SAP.0000000000002430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。